PDX Model DetailsTM00096

Request information on the availability of this model.

PDX Model Summary

Model Details
Model ID (Previous ID)
TM00096 (BR0851F)
Initial Diagnosis
Invasive ductal carcinoma
Final Diagnosis
Invasive ductal carcinoma
Stage/Grade
AJCC IIA / Grade:3
Primary Site
Breast
Sample Site
Lung
Tumor Type
Metastatic

Publications citing this model

 Malcolm, J; et al. Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX). PeerJ. 2019 Mar 28;7:e6586.  10.7717/peerj.6586

Patient
Sex
Female
Age (at time of tissue collection)
52
Race/Ethnicity
White / Hispanic
Treatment Naïve?
No
Current Smoker/Former Smoker
Unknown / Unknown

Engraftment
Host Strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(aka NSG or NOD Scid gamma)
Sample Type
Surgical resection (fragment)
Engraftment Site
no data

Molecular Data (Engrafted Tumor)

Variants

Gene Expression

Platforms: RNA_Seq, hg10st

Hatched bars indicate genes with expression levels determined to be mildly affected by alignment calculations. Details.

Gene CNV

CNV Plots

Tumor Mutation Burden
Sample BR0851F004P0 from passage P0 has a TMB score of 8.89
TMB Range
0.0-304.42 (across all JAX PDX models; TMB > 22 is considered high)

Microsatellite Instability
Sample:BR0851F004P0 from passage P0     Score:MSI-S

Gene Fusion
Fusion Genes
Sample BR0851F002P0 has fusion genes MTG1--SCART1, AC005013.1--AC005162.2, MAP7--C3orf33, PDXDC1--NPIPB14P, PKD1--NPIPP1, GCNT2--AL358777.1, AP000345.3--AL353803.2, BOLA2B--SMG1P2, RAI14--GHR, TRIP10--LINC00665, CUL3--FAM124B, GON4L--AL353807.5, AC004951.2--AC004951.3, CHCHD10--VPREB3, LAMC2--AL354953.1, TVP23C--CDRT4, SLC7A5P1--SMG1P2, ARHGEF5--OR2A7, TSTD1--F11R, AC008443.2--AC008443.5, ZNF736--AC073270.2, GUSBP2--AP000346.2, XPO6--COL12A1, AC138512.1--AC025279.2, FAM53A--AC147067.1, NOS1AP--C1orf226, UCHL3--LMO7, ASLP1--AP000346.2, SMURF2P1--LRRC37BP1, HOXC6--HOXC4, ZNF880--AC010332.1, ZNF738--AC010615.1, SHANK3--ACR, PPP1R1B--STARD3, HNRNPUL2--BSCL2, RBM14--RBM4, UBE2J1--GABRR1, KLHL3--SATB1, SOGA1--DSN1, AC011450.1--SLC6A16, RBM14--RBM4B, SCO1--MYH3, AP000347.1--ASLP1, AC025279.2--SNX29P1, LINC01659--AP000344.1, PMF1--BGLAP, EEF1AKMT3--TSFM, PLCH1--AC108729.3, RNASEH1--AC108488.1, MYH9--AC024405.1, POLA2--CDC42EP2, PTPRF--RIMKLA

Model Characterization

Histology

 Summary:
P2 pathology consistent with carcinoma.
Pathologist:
Dr. Regina Gandour-Edwards, University of California, Davis

P0 tumor #002 for PDX model TM00096.
P0 tumor #003 for PDX model TM00096.

P0 tumor #002 for PDX model TM00096; PR marker (negative)
P0 tumor #003 for PDX model TM00096; PR marker (negative)

P0 tumor #002 for PDX model TM00096; ER marker (negative)
P0 tumor #003 for PDX model TM00096; ER marker (negative)

P0 tumor #002 for PDX model TM00096; HER2 (ERBB2) marker (negative)
P0 tumor #003 for PDX model TM00096 ; HER2 (ERBB2) marker (negative)

P2 tumor F002 ID014 for PDX model TM00096 stained for H&E.
P2 tumor F002 ID014 for PDX model TM00096 stained for AE1AE3. Staining was positive.

P2 tumor F002 ID014 for PDX model TM00096 stained for Ki67. Staining was positive.
P2 tumor F002 ID014 for PDX model TM00096 stained for AR. Staining was negative.

Dosing Studies

Circos Plots

Circos plot for P0 tumor #002 from PDX model TM00096 (aka, BR0851)
Circos plot for P0 tumor #004 from PDX model TM00096 (aka, BR0851)